BMY Stock Outperforms Market as Q1 Earnings Approach, Though Profits Expected to Decline
• BMY stock rose 1.33% on Tuesday, outperforming the S&P 500, Dow, and Nasdaq
• Shares are up 4.04% over the past month, beating the Medical sector's 0.63% loss
• BMY earnings expected to decline 25.37% year-over-year when reported on April 25, 2024
• Consensus estimates call for 2024 EPS of $6.61 and revenue of $46.11 billion, down 11.98% and up 2.45% respectively
• BMY currently trades at a Forward P/E of 7.95, representing a discount vs its industry average of 23.53